Cytosorbents
Signal active
Organization
Contact Information
Overview
CytoSorbents Corporation is a publicly-traded, critical care focused therapeutic device company using blood purification to treat life-threatening illnesses. Its purification technology is based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Each polymer bead contains millions of pores and channels that can be modified to remove substances as small as drugs, to substances as large as antibodies.
About
Industries
Biotechnology, Pharmaceutical, Therapeutics
Founded
1997
Employees
101-250
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Cytosorbents headquartered in United States, North America, operates in the Biotechnology, Pharmaceutical, Therapeutics sector. The company focuses on Biotechnology and has secured $13.8B in funding across 132 round(s). With a team of 101-250 employees, Cytosorbents is actively contributing to advancements in Biotechnology. Their latest funding round, Post-IPO Debt - Cytosorbents, raised $1.1M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
11
Investors
0
Lead Investors
0
Total Funding Amount
$104.8M
Details
0
Cytosorbents has raised a total of $104.8M in funding over 0 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|
Investors
Cytosorbents is funded by 12 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Cytosorbents | - | FUNDING ROUND - Cytosorbents | 15.0M |
| Avenue Capital Group | - | FUNDING ROUND - Avenue Capital Group | 15.0M |
| Cytosorbents | - | FUNDING ROUND - Cytosorbents | 5.0M |
| Bridge Bank | - | FUNDING ROUND - Bridge Bank | 5.0M |
Recent Activity
There is no recent news or activity for this profile.